Bank of New York Mellon’s Cellectar Biosciences CLRB Stock Holding History

Bank of New York Mellon’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-401	Closed	-$17.2K	–	4396
2023 Q1	$17.2K	Hold	401	–	–	﹤0.01%	4322
2022 Q4	$20.6K	Sell	401 -3	-0.7%	-$180	﹤0.01%	4353
2022 Q3	$41K	Hold	404	–	–	﹤0.01%	4353
2022 Q2	$49K	Sell	404 -2	-0.5%	-$286	﹤0.01%	4345
2022 Q1	$84K	Hold	406	–	–	﹤0.01%	4437
2021 Q4	$81K	Hold	406	–	–	﹤0.01%	4437
2021 Q3	$113K	Buy	406 +311	+327%	+$94.9K	﹤0.01%	4308
2021 Q2	$34K	Hold	95	–	–	﹤0.01%	4365
2021 Q1	$46K	Sell	95 -11	-10%	-$6.54K	﹤0.01%	4273
2020 Q4	$66K	Buy	+106	New	+$48.7K	﹤0.01%	4126

Other funds holding CLRB

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

1WM

1900 Wealth Management San Antonio, Texas $1.8B AUM 19.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon's CLRB Position: Q2 2023 in Review

Bank of New York Mellon sold out of Cellectar Biosciences (CLRB) in Q2 2023, closing a stake of 401 shares — an estimated $17.2K sold.

Bank of New York Mellon first reported a position in CLRB in Q4 2020 and held it in 10 quarters. The position peaked at $113K in Q3 2021. 20 funds tracked by Wall St. Rank hold CLRB as of Q2 2023.

Bank of New York Mellon reported no remaining Cellectar Biosciences position as of Q2 2023 after selling out during the quarter.
Bank of New York Mellon sold 401 Cellectar Biosciences shares in Q2 2023, an estimated $17.2K.
Bank of New York Mellon first reported a position in Cellectar Biosciences in Q4 2020 and held it in 10 quarters.
Bank of New York Mellon's Cellectar Biosciences position peaked at $113K in Q3 2021.
20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.